undamentalytics Newsletter
Sign in

Humacyte, Inc. balance sheet

At the end of fiscal 2025, Humacyte, Inc. had total assets of $116m, total liabilities of $113m and shareholders' equity of $3.1m. It held $50.5m in cash against $35.4m of debt: net cash of $15.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents455080
Receivables000
Inventory0147
Total current assets486893
Total assets138116138
Accounts payable454
Total current liabilities201815
Long-term debt03536
Total debt633536
Total liabilities191113107
Shareholders' equity−53331
Net debt (negative = net cash)18−15−44
Shares outstanding130m193m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: HUMA vs KRSACLGN vs HUMAHUMA vs KRRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Humacyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Humacyte, Inc.